Segui
Maria Kavallaris
Maria Kavallaris
Children's Cancer Institute and Australian Centre for NanoMedicine, UNSW Sydney
Email verificata su ccia.unsw.edu.au
Titolo
Citata da
Citata da
Anno
Microtubules and resistance to tubulin-binding agents
M Kavallaris
Nature Reviews Cancer 10 (3), 194-204, 2010
11272010
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
M Kavallaris, DY Kuo, CA Burkhart, DL Regl, MD Norris, M Haber, ...
The Journal of clinical investigation 100 (5), 1282-1293, 1997
7561997
Metronomic chemotherapy: new rationale for new directions
E Pasquier, M Kavallaris, N Andr
Nature reviews Clinical oncology 7 (8), 455-465, 2010
6722010
Movers and shakers: cell cytoskeleton in cancer metastasis
CM Fife, JA McCarroll, M Kavallaris
British journal of pharmacology 171 (24), 5507-5523, 2014
4702014
Minimum information reporting in bio–nano experimental literature
M Faria, M Bjrnmalm, KJ Thurecht, SJ Kent, RG Parton, M Kavallaris, ...
Nature nanotechnology 13 (9), 777-785, 2018
4452018
Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells
KM Murphy, V Ranganathan, ML Farnsworth, M Kavallaris, RB Lock
Cell Death & Differentiation 7 (1), 102-111, 2000
3962000
Microtubules and their role in cellular stress in cancer
AL Parker, M Kavallaris, JA McCarroll
Frontiers in oncology 4, 153, 2014
3652014
Biologically targeted magnetic hyperthermia: Potential and limitations
D Chang, M Lim, JACM Goos, R Qiao, YY Ng, FM Mansfeld, M Jackson, ...
Frontiers in pharmacology 9, 831, 2018
3452018
Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non–small cell lung cancer
PP Gan, E Pasquier, M Kavallaris
Cancer research 67 (19), 9356-9363, 2007
3012007
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
CA Burkhart, M Kavallaris
Biochimica et biophysica acta 1471 (2), O1-9, 2001
2882001
Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells
M Kavallaris, AS Tait, BJ Walsh, L He, SB Horwitz, MD Norris, M Haber
Cancer research 61 (15), 5803-5809, 2001
2812001
Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol
M Kavallaris, CA Burkhart, SB Horwitz
British journal of cancer 80 (7), 1020-1025, 1999
2551999
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
E Pasquier, J Ciccolini, M Carre, S Giacometti, R Fanciullino, C Pouchy, ...
Oncotarget 2 (10), 797, 2011
2382011
Microtubules: a dynamic target in cancer therapy
E Pasquier, M Kavallaris
IUBMB life 60 (3), 165-170, 2008
2372008
Acid-labile core cross-linked micelles for pH-triggered release of antitumor drugs
Y Chan, T Wong, F Byrne, M Kavallaris, V Bulmus
Biomacromolecules 9 (7), 1826-1836, 2008
2132008
Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood
R Tavallaie, J McCarroll, M Le Grand, N Ariotti, W Schuhmann, E Bakker, ...
Nature nanotechnology 13 (11), 1066-1071, 2018
2072018
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β‐tubulins
S Tommasi, A Mangia, R Lacalamita, A Bellizzi, V Fedele, A Chiriatti, ...
International journal of cancer 120 (10), 2078-2085, 2007
2042007
Role of pancreatic stellate cells in chemoresistance in pancreatic cancer
JA McCarroll, S Naim, G Sharbeen, N Russia, J Lee, M Kavallaris, ...
Frontiers in physiology 5, 141, 2014
1772014
Anticancer therapy with novel tubulin-interacting drugs
M Kavallaris, NM Verrills, BT Hill
Drug Resistance Updates 4 (6), 392-401, 2001
1652001
Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release
JS Basuki, HTT Duong, A Macmillan, RB Erlich, L Esser, MC Akerfeldt, ...
ACS nano 7 (11), 10175-10189, 2013
1632013
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–20